How to build a “European Amgen”

Aphea.Bio focusses on plant-bacterial interactions for the development of biopesticides and biostimulants based on naturally occurring microorganisms.

Many biotech management teams fail to reach out to investors in a clear and appealing way.

Despite the initial intent of charitable foundations to be not-for-profit, some of them tend to morph into organizations with bigger aspirations.

Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovations, companies, and their economic benefits from being transferred to regions outside Europe, many national and international European initiatives are in place. The question remains whether this is sufficient to fundamentally improve Europe’s currently underfunded biotech ecosystem. The biotech investment specialists of V-Bio Ventures take us through Europe’s biotech investment landscape.

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, convinced major investors, such as Bill Gates and Jeff Bezos, of the technology’s potential. A whopping $1 billion was gathered in the company’s series B financing round. Yet, do Grail and its technology deserve this huge ticket?

Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.

Only one year after its inception, the life science investment fund V-Bio Ventures made its first investments in three companies and announced the final closing [...]